Claims
- 1. A method for reducing morphogen-dependent bone formation of a cell comprising an extracellular surface in contact with a medium, said method comprising the step of:
contacting said medium with an antagonist of a bone morphogenie protein (BMP) selected from the group consisting of human BMP2 and human BMP4, said antagonist produced exogenously from said cell and comprising SEQ ID NO:2, 4, 6, 8 or 9 or a deletion mutant of a sequence selected from the group consisting of SEQ ID NO:2 or 8 wherein said deletion mutant encodes a polypeptide that retains at least 8 contiguous amino acids of said SEQ ID NO:2 or 8 and is sufficient to specifically bind and antagonize said BMP, under conditions whereby said morphogen-dependent bone formation is reduced; and measuring a resultant reduction of said morphogen-dependent bone formation.
- 2. A method for reducing morphogen-dependent bone formation of a cell comprising an extracellular surface in contact with a medium, said method comprising the step of:
contacting said medium with an antagonist of a bone morphogenic protein (BMP) selected from the group consisting of human BMP2 and human BMP4, said antagonist produced exogenously from said cell and comprising SEQ ID NO:2, or a deletion mutant of SEQ ID NO:2 wherein said deletion mutant encodes a polypeptide that retains at least 8 contiguous amino acids of SEQ ID NO:2 and is sufficient to specifically bind and antagonize said BMP, under conditions whereby said morphogen-dependent bone formation is reduced; and measuring a resultant reduction of said morphogen-dependent bone formation.
- 3. A method for reducing morphogen-dependent bone formation of a cell comprising an extracellular surface in contact with a medium, said method comprising the step of:
contacting said medium with an antagonist of a bone morphogenic protein (BMP) selected from the group consisting of human BMP2 and human BMP4, said antagonist produced exogenously from said cell and comprising SEQ ID NO:8, or a deletion mutant of SEQ ID NO:8 wherein said deletion mutant encodes a polypeptide that retains at least 8 contiguous amino acids of SEQ ID NO:8 and is sufficient to specifically bind and antagonize said BMP, under conditions whereby said morphogen-dependent bone formation is reduced; and measuring a resultant reduction of said morphogen-dependent bone formation.
- 4. A method according to claim 1, wherein said cell is in situ and said medium is a physiological fluid comprising said BMP.
- 5. A method according to claim 2, wherein said cell is in situ and said medium is a physiological fluid comprising said BMP.
- 6. A method according to claim 3, wherein said cell is in situ and said medium is a physiological fluid comprising said BMP.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuing application under 35USC120 of U.S. Ser. No. 09/040,229, filed Mar. 13, 1998, which is a continuing application under 35USC120 of U.S. Ser. No. 08/795,501 filed Feb. 5, 1997, the specifications of which are incorporated by reference.
Government Interests
[0002] The research carried out in the subject application was supported in part by grants from the National Institutes of Health. The government may have rights in any patent issuing on this application.
Continuations (2)
|
Number |
Date |
Country |
Parent |
09040229 |
Mar 1998 |
US |
Child |
10159749 |
May 2002 |
US |
Parent |
08795501 |
Feb 1997 |
US |
Child |
09040229 |
Mar 1998 |
US |